Participated · Seed · Aug 2026

Shiplog develops Ada, an AI agent that continuously builds a live, individualised profile for each customer and decides next-best actions across marketing, product, onboarding and customer success. The platform plugs into existing stacks such as Salesforce, HubSpot, Snowflake, Shopify and Stripe to aggregate signals and personalise communications and in-product experiences. Shiplog has run pilots that analysed more than four million events across roughly 1,000 customers to prove the system at scale and has seen early traction in fintech and cybersecurity verticals. The founders, Khushi Mehta and Mehdi Gribaa, met during Entrepreneurs First and operate from Station F. Financially, the company completed a pre-seed round of about $1 million backed by Kima Ventures, Project Europe and several other angel and seed investors to fund product development and commercial roll-out ahead of public launch.

Participated · Seed · May 2026

Leadbay offers a solution for sales teams to find and target companies with zero or minimal digital footprints. The company is YC-backed, as noted in coverage of its recent fundraise. Public reporting focused on its pitch deck and the $4.2M raise rather than product technicals or go-to-market metrics. The articles did not provide information on revenue, user counts, founding year, location, or detailed future plans. No additional operating or financial metrics were disclosed in the coverage.

Participated · Equity · Apr 2026

Cobl.ai provides a multi-agent AI platform that transforms briefs and raw data into structured, brand-compliant commercial documents in minutes by orchestrating specialized agents for drafting, layout, QA, compliance and visual research. The platform integrates with tools such as Notion, Microsoft Teams, Salesforce and Gmail to access internal client resources and personalize outputs while keeping the salesperson in control through agent prompts and checkpoints. Founded in 2020 by Damien Hontang and Quentin Marquet and formerly known as Thinkeo, the company repositioned from building complex enterprise AI applications to focusing specifically on sales document automation. Cobl.ai counts customers including Orano, Free and Econocom. Its product aims to save sales teams time on proposals, RFP responses and client presentations while improving quality and consistency. The company plans further product enhancements so agents can develop deep, client-specific knowledge to better mirror the salesperson's understanding.

Participated · Series A · Oct 2025

Founded in 2021 by Alexandros Pantalis and Adèle James, Phagos engineers bacteriophage (phage) treatments through a proprietary platform that combines microbiology with artificial intelligence. Its patented AI analyses complete phage and bacterial genomes to predict interactions and design precise, adaptable therapies as pathogens evolve. The company’s first commercial focus is veterinary medicine, where it has already secured regulatory authorisation to market personalised phage-based treatments aimed at reducing antibiotic use in livestock. Longer term, Phagos intends to expand these solutions to human health applications. With antimicrobial resistance driving millions of deaths and heavy economic costs, management positions the technology as a scalable global standard for bacterial infection control. The recent €25 million Series A financing provides capital to scale veterinary product deployment, advance the next generation of its AI, and grow the team to support market launches and international expansion. No operating metrics such as revenue or user counts were disclosed in the article.

Participated · Series A · Feb 2025

Founded in 2023, Paris-based Spore Biotechnologies (branded Spore.Bio) builds full-stack platforms that combine proprietary biophotonics hardware with machine-learning models to identify microbes at the single-cell level in real time. Traditional microbiological assays take five to twenty days and require off-site labs; Spore’s solution offers immediate, on-site diagnostics by capturing visible, UV, and near-infrared spectral fingerprints from samples and analyzing them with a foundational model trained on millions of images. The technology integrates with an in-house dashboard that gives manufacturers continuous, traceable insight into microbial activity. To accelerate scientific discovery, the company has created Spore.Labs, an AI-native research arm that will publish open datasets and collaborate with academic and clinical partners. Spore.Bio has raised €29.9 million ($35 million) in equity financing to date, including a €22 million Series A led by Singular in February 2023. The company has begun hiring aggressively, expecting to add 30 scientists by 2026. Its new funding and access to Google Cloud resources further strengthen its R&D and commercialization roadmap.